ALPHA COGNITION INC
ACOGNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $4.50 β $10.14
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 21.8M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $8M
- P/E Ratio
- β
- P/S Ratio
- 13.0x
- EPS (TTM)
- $-1.09
- Dividend Yield
- β
- Dilution (1yr)
- +98.4%
ALPHA COGNITION INC
ACOGAbout ALPHA COGNITION INC
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.